Building a healthier future
At Axonia Strategies, every breakthrough moves us closer to a future where patients gain more time with those they love. Drawing on 12+ years of neuroscience drug discovery and development, we’ve advanced programs from the lab bench through IND and into the clinic. We specialize in turning complex science into patient-focused solutions, helping teams overcome obstacles and accelerate progress. We don’t just consult; we partner. With strategy, rigor, and creativity, we turn bold ideas into transformative therapies.
Gavin Daigle, PhD
A neuroscience leader with 12+ years of experience, he has advanced CNS drug discovery and translational programs from concept through IND and into early clinical development. He has built and led teams across pharma and biotech, including Rapport Therapeutics, Sensorium, Remix Therapeutics, Neuron23, and AbbVie, driving first-in-class therapies in neuropsychiatry and neurodegeneration. His expertise spans translational medicine, biomarker strategy, and early development leadership, with a proven record of guiding programs from bold scientific ideas to clinical impact.
Bahareh Eftekharzadeh, PharmD, PhD
A biotech entrepreneur and translational scientist with 12+ years of experience, she has advanced neuroscience drug discovery and biomarker programs from concept through IND and into the clinic. She has helped launch and lead multiple ventures, including Nereid Therapeutics and Neuron23, while launching new platform through Axonia Strategies. Her expertise spans company creation, executive R&D leadership, and translational strategy, with a proven record of guiding teams from bold ideas to impactful therapies.Contact us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!